165 related articles for article (PubMed ID: 32170841)
21. Females display relatively preserved muscle quality compared with males during the onset and early stages of C26-induced cancer cachexia.
Cabrera AR; Deaver JW; Lim S; Morena da Silva F; Schrems ER; Saling LW; Tsitkanou S; Rosa-Caldwell ME; Wiggs MP; Washington TA; Greene NP
J Appl Physiol (1985); 2023 Sep; 135(3):655-672. PubMed ID: 37535708
[TBL] [Abstract][Full Text] [Related]
22. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia.
Constantinou C; Fontes de Oliveira CC; Mintzopoulos D; Busquets S; He J; Kesarwani M; Mindrinos M; Rahme LG; Argilés JM; Tzika AA
Int J Mol Med; 2011 Jan; 27(1):15-24. PubMed ID: 21069263
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.
Martin A; Freyssenet D
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):252-273. PubMed ID: 33783983
[TBL] [Abstract][Full Text] [Related]
24. PGC1α overexpression preserves muscle mass and function in cisplatin-induced cachexia.
Huot JR; Pin F; Chatterjee R; Bonetto A
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2480-2491. PubMed ID: 35903870
[TBL] [Abstract][Full Text] [Related]
25. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
26. Cachectic skeletal muscle response to a novel bout of low-frequency stimulation.
Puppa MJ; Murphy EA; Fayad R; Hand GA; Carson JA
J Appl Physiol (1985); 2014 Apr; 116(8):1078-87. PubMed ID: 24610533
[TBL] [Abstract][Full Text] [Related]
27. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
28. Mouse models of cancer-induced cachexia: Hind limb muscle mass and evoked force as readouts.
Jourdain M; Melly S; Summermatter S; Hatakeyama S
Biochem Biophys Res Commun; 2018 Sep; 503(4):2415-2420. PubMed ID: 29969629
[TBL] [Abstract][Full Text] [Related]
29. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
30. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle.
Roberts BM; Frye GS; Ahn B; Ferreira LF; Judge AR
Biochem Biophys Res Commun; 2013 Jun; 435(3):488-92. PubMed ID: 23673294
[TBL] [Abstract][Full Text] [Related]
31. Extracellular superoxide dismutase ameliorates skeletal muscle abnormalities, cachexia, and exercise intolerance in mice with congestive heart failure.
Okutsu M; Call JA; Lira VA; Zhang M; Donet JA; French BA; Martin KS; Peirce-Cottler SM; Rembold CM; Annex BH; Yan Z
Circ Heart Fail; 2014 May; 7(3):519-30. PubMed ID: 24523418
[TBL] [Abstract][Full Text] [Related]
32. Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia.
Lima M; Sato S; Enos RT; Baynes JW; Carson JA
J Appl Physiol (1985); 2013 Mar; 114(6):824-8. PubMed ID: 23329823
[TBL] [Abstract][Full Text] [Related]
33. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
34. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6 and cachexia in ApcMin/+ mice.
Baltgalvis KA; Berger FG; Pena MM; Davis JM; Muga SJ; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2008 Feb; 294(2):R393-401. PubMed ID: 18056981
[TBL] [Abstract][Full Text] [Related]
36. Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice.
Martin A; Castells J; Allibert V; Emerit A; Zolotoff C; Cardot-Ruffino V; Gallot YS; Vernus B; Chauvet V; Bartholin L; Schaeffer L; Durieux AC; Hourdé C; Favier FB; Mazelin L; Freyssenet D
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1686-1703. PubMed ID: 35277933
[TBL] [Abstract][Full Text] [Related]
37. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?
Mueller TC; Bachmann J; Prokopchuk O; Friess H; Martignoni ME
BMC Cancer; 2016 Feb; 16():75. PubMed ID: 26856534
[TBL] [Abstract][Full Text] [Related]
39. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.
Huot JR; Novinger LJ; Pin F; Narasimhan A; Zimmers TA; O'Connell TM; Bonetto A
JCI Insight; 2020 May; 5(9):. PubMed ID: 32298240
[TBL] [Abstract][Full Text] [Related]
40. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
